drugset

drugset / Trial / NCT02171728

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

NCT02171728 ↗

Phase 1 Completed 30 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992

Timeline

Start: 2004-11
Primary completion: 2006-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Afatinib	Small molecule	—	Oral

Indications